300313 ST天山生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-57.698-30.069-33.810-21.0752.770
总资产报酬率 ROA (%)-9.101-6.793-8.700-4.1800.411
投入资产回报率 ROIC (%)-19.851-13.037-14.583-8.6251.487

边际利润分析
销售毛利率 (%)-0.60916.98614.1667.08915.772
营业利润率 (%)-50.839-13.572-36.988-26.047-4.878
息税前利润/营业总收入 (%)-42.353-6.278-21.879-13.4349.318
净利润/营业总收入 (%)-58.079-16.061-41.952-28.1491.538

收益指标分析
经营活动净收益/利润总额(%)67.43880.28973.521117.534-529.547
价值变动净收益/利润总额(%)-6.406-15.06926.411-2.921225.351
营业外收支净额/利润总额(%)5.2333.3407.3241.479340.526

偿债能力分析
流动比率 (X)0.4100.4840.5210.6330.100
速动比率 (X)0.1510.1680.2810.5270.039
资产负债率 (%)84.59977.16271.71471.35383.565
带息债务/全部投入资本 (%)58.54450.43447.53553.899--
股东权益/带息债务 (%)45.92580.67495.85076.71372.425
股东权益/负债合计 (%)13.68425.55935.29036.55820.446
利息保障倍数 (X)-3.751-0.809-1.213-1.0331.278

营运能力分析
应收账款周转天数 (天)43.67525.98482.71561.3300.000
存货周转天数 (天)250.811199.698228.050133.9300.000